Outcomes of Pelvic Exenteration for Recurrent or Persistent Cervical Cancer: Revisiting Curative approach in the Era of Advancing Palliative Options
- 2 August 2025
- journal article
- research article
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (5) , 1045-1051
Abstract
This study aimed to evaluate the outcomes of pelvic exenteration (PE) in patients with recurrent or persistent cervical cancer, with emphasis on whether modern advancements—timely diagnosis, surgical refinement, and multidisciplinary perioperative care—have addressed traditional concerns regarding morbidity, quality of life, and survival. This was a retrospective study conducted at a tertiary cancer center from January 2021 to December 2023. In total, 25 patients who underwent PE for recurrent (60%) or persistent (40%) cervical cancer were included. All patients were evaluated with PET-CT and pelvic MRI for operability. Tissue diagnosis was confirmed using TRUS, TVS, EUA, or cystoscopic biopsy. Surgical outcomes, complications, margin status, survivals, and quality of life were assessed using EORTC QLQ-C30 and Stoma-QOL tools. Median age was 58 years. Total PE was performed in 56%, anterior in 40%, and posterior in 4%; 28% were robotic. R0 resection was achieved in 100%. Major complications occurred in 8%, with no perioperative mortality. Mean operative time was 6.4 h and mean blood loss was 650 ml. At a median follow-up of 18.5 months, 76% of patients were alive and 72% were disease free. Median DFS and OS were 18.5 months. QoL improved significantly over time, with global health scores increasing from 69.5 to 80.8, and stoma-related QoL indices from 77.7 to 83.3%. With modern advances, PE offers a curative option with acceptable morbidity and improved quality of life. It should be actively considered in eligible patients rather than deferred in favor of palliative systemic therapies.Keywords
This publication has 11 references indexed in Scilit:
- Clinical outcomes of pelvic exenteration for gynecologic malignanciesGynecologic Oncology, 2023
- Pedicled vastus lateralis myocutaneous flap for sacropelvic defects after wide oncologic resection: Wound complications and outcomesJournal of Surgical Oncology, 2022
- Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohortGynecologic Oncology, 2021
- Salvage robotic anterior pelvic exenteration for cervical cancer: technique and feasibilityJournal of Robotic Surgery, 2021
- Survival After Pelvic Exenteration for Cervical CancerInternational Journal of Gynecological Cancer, 2017
- Survival After Curative Pelvic Exenteration for Primary or Recurrent Cervical CancerInternational Journal of Gynecological Cancer, 2014
- The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenterationGynecologic Oncology, 2013
- Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenterationEuropean Radiology, 2013
- Pelvic exenteration: Ten-year experience at the European Institute of Oncology in MilanGynecologic Oncology, 2009
- Pelvic exenteration for gynaecological tumours: achievements and unanswered questionsThe Lancet Oncology, 2006